Perpetual Ltd Sells 594 Shares of Humana Inc. (NYSE:HUM)

Perpetual Ltd decreased its stake in Humana Inc. (NYSE:HUM) by 0.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 99,726 shares of the insurance provider’s stock after selling 594 shares during the period. Perpetual Ltd owned about 0.08% of Humana worth $31,587,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Mendota Financial Group LLC grew its stake in shares of Humana by 9.2% in the second quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock worth $119,000 after purchasing an additional 27 shares during the last quarter. Aurora Investment Counsel raised its holdings in shares of Humana by 1.3% during the fourth quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after purchasing an additional 29 shares during the last quarter. Capital Advisors Ltd. LLC lifted its holdings in shares of Humana by 17.0% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock valued at $80,000 after buying an additional 31 shares during the period. EP Wealth Advisors LLC boosted its holdings in shares of Humana by 1.6% in the fourth quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock worth $1,050,000 after buying an additional 37 shares during the last quarter. Finally, CarsonAllaria Wealth Management Ltd. grew its position in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Up 0.9 %

HUM stock opened at $245.43 on Thursday. Humana Inc. has a one year low of $213.31 and a one year high of $530.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The firm has a market cap of $29.57 billion, a PE ratio of 15.28, a P/E/G ratio of 2.44 and a beta of 0.50. The firm’s fifty day moving average is $329.03 and its 200 day moving average is $341.40.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.94 EPS. On average, research analysts forecast that Humana Inc. will post 16.01 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.44%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio is currently 22.04%.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research report on Thursday, October 3rd. Royal Bank of Canada cut their target price on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday. Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 price objective on shares of Humana in a report on Tuesday, October 1st. Morgan Stanley assumed coverage on Humana in a report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 target price for the company. Finally, JPMorgan Chase & Co. increased their price objective on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, eighteen have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $324.86.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.